7 March 2026·PIB

8th Janaushadhi Diwas Celebrated Across the Country with Enthusiastic Participation

In this note

1. At a Glance

Janaushadhi Diwas is observed annually on 7 March to mark the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), the flagship scheme for affordable generic medicines. [1][2]
Implemented by Pharmaceuticals & Medical Devices Bureau of India (PMBI) under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. [1][3]
UPSC relevance: GS-II (health, government schemes), GS-III (pharma sector, generics, drug pricing). [1]

The 8th Janaushadhi Diwas was celebrated on 7 March 2026 across India, marking culmination of week-long Janaushadhi Saptah 2026; Union Minister J P Nadda announced target to expand the network to 25,000 Janaushadhi Kendras by next year. [1]
Programs were organised at 25 locations nationwide; awards presented to best-performing Kendra owners by Nadda and MoS Anupriya Patel. [1]

Launched as Jan Aushadhi Campaign in 2008 by the Department of Pharmaceuticals; rebranded and revamped as PMBJP in 2015–16. [3]
Operationalised through PMBI (a Society under Department of Pharmaceuticals), formerly BPPI. [1]
First Janaushadhi Diwas observed on 7 March 2019; hence 2026 marks the 8th edition. [2]
10,000th Kendra inaugurated by PM at AIIMS Deoghar in 2023, with target raised from 10,000 → 25,000. [4]

Parent body: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. [1]
Implementing agency: Pharmaceuticals & Medical Devices Bureau of India (PMBI). [1]
Annual Diwas date: 7 March. [2]
Janaushadhi Saptah 2026: observed 1–7 March 2026; health camps at 250+ locations between 1–5 March 2026. [2]
Operational Kendras: >18,000 across India (as of March 2026). [2]
Target: 25,000 Kendras (revised timeline announced; expansion goal reiterated by Min. Nadda). [1][4]
Product basket (Feb 2025): 2,047 drugs + 300 surgical/consumable items. [2]
Sales milestone: Crossed Rs. 1,000 crore in FY 2023-24. [5]
Women empowerment: >8,000 Kendras run by women entrepreneurs. [2]
Pricing principle: Generic medicines priced 50–90% lower than branded equivalents (PMBJP design). [3]

Economic / Health Financing

Reduces out-of-pocket health expenditure (currently ~47% in India); generics at fraction of branded MRP cut household drug bills. [3]
Cumulative savings to citizens estimated in thousands of crores; FY24 sales of Rs 1,000+ crore implies ~Rs 5,000+ crore notional savings. [5]

Social / Equity

Expansion of 8,000+ women-run Kendras advances female entrepreneurship in tier-2/3 towns. [2]
Coverage of 3,579 blocks across 406 districts in 26 States/UTs under fresh openings. [6]

Administrative

Eligibility liberalised: individuals, pharmacists, NGOs, hospitals, SHGs can open Kendras with incentives up to Rs 5 lakh. [3]
Quality assured via WHO-GMP certified suppliers and NABL-accredited lab testing. [3]

Scientific / Industrial

Aligns with India's "Pharmacy of the World" positioning by promoting domestic generic manufacturers. [3]
Strengthens National Pharmaceutical Pricing Authority (NPPA) objective of drug affordability. [3]

March 2025: 7th Janaushadhi Diwas with theme "जन औषधि: दाम कम, दवाई उत्तम"; flagged off by Min. Nadda in New Delhi. [7][8]
2024: 13,822 Kendras operational. [9]
1–5 March 2026: Health camps at 250+ locations under Janaushadhi Saptah. [2]
7 March 2026: 8th Janaushadhi Diwas; 25,000-Kendra expansion target reiterated. [1]

Janaushadhi Diwas: observed on 7 March every year. [2]
First Janaushadhi Diwas observed in 2019 → 2026 = 8th edition. [1]
Scheme: Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), launched in current form in 2015–16; campaign origin 2008. [3]
Implementing agency: PMBI (Pharmaceuticals & Medical Devices Bureau of India) — NOT NPPA, NOT CDSCO. [1]
Parent ministry: Ministry of Chemicals & Fertilizers (Dept of Pharmaceuticals) — NOT Ministry of Health. [1]
Operational Kendras (Mar 2026): >18,000. [2]
Expansion target: 25,000 Kendras. [1][4]
Product basket: 2,047 medicines + 300 surgicals/consumables. [2]
Sales FY 2023-24: crossed Rs 1,000 crore. [5]
10,000th Kendra opened at AIIMS Deoghar (Jharkhand) by PM Modi. [4]
Generics priced 50–90% cheaper than branded. [3]
>8,000 Kendras run by women. [2]
Saptah 2025 theme: "दाम कम, दवाई उत्तम". [7]

GS-II: Government policies/interventions for development in health sector; issues relating to health.
GS-III: Indian pharmaceutical industry; inclusive growth.

Possible stems:

"PMBJP has redefined affordability in India's healthcare landscape, but its impact remains uneven." Critically examine.
Discuss the role of generic medicines in reducing out-of-pocket health expenditure in India, with reference to PMBJP.
Evaluate the institutional architecture (PMBI, NPPA, CDSCO) supporting affordable medicines in India.

National Pharmaceutical Pricing Authority (NPPA) — price ceiling regulator, complements PMBJP.
Drug Price Control Order (DPCO) 2013 — statutory basis of essential drug pricing.
National List of Essential Medicines (NLEM) 2022 — defines scheduled drugs.
Ayushman Bharat (PM-JAY) — demand-side health financing pillar.
Production-Linked Incentive (PLI) for Pharma & APIs — supply-side support.
CDSCO / Drugs & Cosmetics Act 1940 — regulatory framework for quality.
Out-of-Pocket Expenditure & National Health Accounts — outcome metric.
WHO-GMP certification — quality benchmark for Janaushadhi suppliers.

Wrong ministry: PMBJP is under Chemicals & Fertilizers, NOT Ministry of Health & Family Welfare.
Confusing PMBI (implementer) with NPPA (price regulator) or CDSCO (drug regulator).
Diwas date: 7 March (not 1 March, which is start of Saptah).
Launch year: campaign began 2008; relaunched as PMBJP in 2015–16 — not 2019 (that's the first Diwas).
Misremembering target as 10,000 (achieved 2023) instead of revised 25,000.